GSK Partners With University Spin-Off | March 30, 2009 Issue - Vol. 87 Issue 13 | Chemical & Engineering News
Volume 87 Issue 13 | p. 14 | Concentrates
Issue Date: March 30, 2009

GSK Partners With University Spin-Off

Department: Business

GlaxoSmithKline and University College London spin-off Pentraxin Therapeutics are developing a small-molecule-antibody conjugate for treating amyloidosis, a rare and often fatal disease caused by abnormal protein buildup in the body. The companies have linked Pentraxin's small-molecule drug carboxy pyrrolidine hexanoyl pyrrolidine carboxylic acid, or CHPHC, to a mouse antibody that seeks out amyloid deposits. The combination rapidly cleared the deposits in mice. The collaborators' next step is to convert the mouse antibody into one that can be used in humans.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment